AbbVie News

$1000 Invested In This Stock 10 Years Ago Would Be Worth $3,100 Today

AbbVie (NYSE:ABBV) has outperformed the market over the past 10 years by 1.32% on an annualized basis producing an average annual return of 11.69%. Currently, AbbVie has a market capitalization of $28

Benzinga14:30 ET

CVS Stresses 'Margins Over Membership' to Offset Medicare Pressure

Yahoo FinanceMay 1 13:46 ET

Here Is What to Know Beyond Why AbbVie Inc. (ABBV) Is a Trending Stock

Yahoo FinanceMay 1 09:00 ET

Express News | NYSE Order Imbalance 125408.0 Shares on Sell Side

ReutersApr 30 15:50 ET

Express News | CNBC Halftime Report Final Trades: Amazon.Com, RTX, AbbVie

BenzingaApr 30 13:01 ET

Despite Lower Earnings Than Five Years Ago, AbbVie (NYSE:ABBV) Investors Are up 156% Since Then

It might be of some concern to shareholders to see the AbbVie Inc. (NYSE:ABBV) share price down 11% in the last month. But that doesn't change the fact that the returns over the last five years hav

Simply Wall StApr 30 08:07 ET

Genstar Names Keith Martino to Strategic Advisory Board

Experienced Pharma Executive to Advise on the Firm's Healthcare Investments SAN FRANCISCO, April 30, 2024 /PRNewswire/ -- Genstar Capital, a leading private equity firm focused on investments in targ

PR NewswireApr 30 08:00 ET

Earnings Beat: AbbVie Inc. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models

Yahoo FinanceApr 30 06:21 ET

Express News | Abbvie Inc. : Barclays Cuts Target Price to $187 From $195

ReutersApr 30 05:19 ET

Analysts Offer Insights on Healthcare Companies: AbbVie (ABBV), Molina Healthcare (MOH) and Cytokinetics (CYTK)

TipRanksApr 30 03:11 ET

Hold Rating on AbbVie Amidst Humira Concerns and Biosimilar Competition Despite Strong Pipeline Prospects

TipRanksApr 30 02:05 ET

AbbVie Reinforces Commitment to Science and Innovation With a €150 Million Euro Investment in New Cutting-Edge Research and Development Facility in Germany

New state-of-the-art research and development (R&D) facility at Ludwigshafen to expand discovery and development of new medicines across core therapeutic areas Investment reinforces the importance of

abbvieApr 30 00:00 ET

Express News | NYSE Order Imbalance 99441.0 Shares on Buy Side

ReutersApr 29 15:50 ET

Peeling Back The Layers: Exploring AbbVie Through Analyst Insights

In the latest quarter, 8 analysts provided ratings for AbbVie (NYSE:ABBV), showcasing a mix of bullish and bearish perspectives.The table below provides a snapshot of their recent ratings, showcasing

BenzingaApr 29 11:01 ET

Express News | BMO Capital Maintains Outperform on AbbVie, Lowers Price Target to $180

BenzingaApr 29 10:09 ET

AbbVie Analyst Ratings

Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 04/29/2024 11.93% BMO Capital $195 → $180 Maintains Outperform 03/27/2024 21.26% Barclays $185 → $195 Main

BenzingaApr 29 10:08 ET

These Pharmaceutical Firms Are on Sale: AbbVie, Pfizer, and Gilead

Baystreet.caApr 29 09:52 ET

Barclays Adjusts Price Target on AbbVie to $187 From $195

AbbVie (ABBV) has an average rating of outperform and price targets ranging from $161 to $206, according to analysts polled by Capital IQ. Price: 159.60, Change: -0.02, Percent Change: -0.01

MT NewswiresApr 29 08:24 ET

Analysts' Top Healthcare Picks: AbbVie (ABBV), Wave Life Sciences (WVE)

TipRanksApr 29 07:53 ET

Buy Rating Affirmed: AbbVie's Strong Performance and Positive Growth Outlook

TipRanksApr 29 07:27 ET